BR112014017985A8 - Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer - Google Patents

Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer

Info

Publication number
BR112014017985A8
BR112014017985A8 BR112014017985A BR112014017985A BR112014017985A8 BR 112014017985 A8 BR112014017985 A8 BR 112014017985A8 BR 112014017985 A BR112014017985 A BR 112014017985A BR 112014017985 A BR112014017985 A BR 112014017985A BR 112014017985 A8 BR112014017985 A8 BR 112014017985A8
Authority
BR
Brazil
Prior art keywords
combination
tautomer
compounds
antistrogen
cancer
Prior art date
Application number
BR112014017985A
Other languages
English (en)
Other versions
BR112014017985A2 (pt
Inventor
Yovine Alejandro
Squires Matthew
Wynnette Reddick Catherine
Zhang Yong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014017985A2 publication Critical patent/BR112014017985A2/pt
Publication of BR112014017985A8 publication Critical patent/BR112014017985A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

COMBINAÇÃO DE UM INIBIDOR DE RTK COM UM ANTIESTROGÊNIO E USO DA MESMA PARA O TRATAMENTO DE CANCER. A presente invenção refere-se a uma combinação farmacêutica que compreende (a) um inibidor de |RTK selecionado a partir do grupo que consiste de compostos da Fórmula I ou um tautômero dos mesmos, compostos da Fórmula II ou um tautômero dos mesmos, compostos da Fórmula II ou um tautômero dos mesmos, um sal farmaceuticamente aceitável do composto, um sal farmaceuticamente aceitável do tautômero ou uma mistura dos mesmos, e (b) um ou mais compostos antiestrogênio ou um sal farmaceuticamente aceitável do mesmo tal como o tamoxifeno, toremifeno, fulvestrant, raloxifeno ou cloridrato de raloxifeno; os usos de tal combinação no tratamento ou na prevenção de doenças proliferativas e métodos para o tratamento de um sujeito que esteja sofrendo de uma doença proliferativa, e métodos para o tratamento de um sujeito sofrendo de uma doença proliferativa compreendo a administração de uma quantidade terapeuticamente efetiva de tal combinação.
BR112014017985A 2012-01-31 2013-01-30 Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer BR112014017985A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261593047P 2012-01-31 2012-01-31
PCT/US2013/023781 WO2013116293A1 (en) 2012-01-31 2013-01-30 Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer

Publications (2)

Publication Number Publication Date
BR112014017985A2 BR112014017985A2 (pt) 2017-06-20
BR112014017985A8 true BR112014017985A8 (pt) 2017-07-11

Family

ID=47679114

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017985A BR112014017985A8 (pt) 2012-01-31 2013-01-30 Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer

Country Status (12)

Country Link
US (1) US20140378422A1 (pt)
EP (1) EP2809312A1 (pt)
JP (1) JP2015505562A (pt)
KR (1) KR20140117457A (pt)
CN (1) CN104093402A (pt)
AU (1) AU2013215251A1 (pt)
BR (1) BR112014017985A8 (pt)
CA (1) CA2861377A1 (pt)
IN (1) IN2014DN05869A (pt)
MX (1) MX2014009303A (pt)
RU (1) RU2014135436A (pt)
WO (1) WO2013116293A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015136016A2 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
MX2018007079A (es) * 2015-12-09 2018-11-12 The Board Of Trustees Of Univ Of Illinois Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno.
KR20240014585A (ko) 2016-03-04 2024-02-01 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
US10208011B2 (en) 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
EP3737377A1 (en) * 2018-01-10 2020-11-18 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
SG11202007591RA (en) 2018-03-28 2020-09-29 Eisai R&D Man Co Ltd Therapeutic agent for hepatocellular carcinoma
US20220047563A1 (en) * 2018-09-13 2022-02-17 Zenith Epigenetics Ltd. Combination therapy for the treatment of estrogen-receptor positive breast cancer
MA54311A (fr) * 2018-11-26 2022-03-02 Taiho Pharmaceutical Co Ltd Procédé thérapeutique et prophylactique contre une tumeur pouvant être traitée par endocrinothérapie faisant appel à une utilisation combinée d'un inhibiteur des récepteurs du facteur de croissance des fibroblastes et d'une endocrinothérapie
KR20230047056A (ko) * 2020-07-31 2023-04-06 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암 치료제
WO2022184146A1 (zh) * 2021-03-03 2022-09-09 正大天晴药业集团股份有限公司 Cdk4/6抑制剂的联用药物组合物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (pt) 1962-09-13
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
ITTV20030095A1 (it) 2003-07-14 2005-01-15 Asolo Spa Calzatura con sottopiede composito.
JP4724665B2 (ja) 2003-11-07 2011-07-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キノリノン化合物を合成する方法
ES2374570T3 (es) * 2005-01-27 2012-02-17 Novartis Vaccines And Diagnostics, Inc. Tratamiento de tumores metastalizados.
MX2007014206A (es) 2005-05-13 2008-02-07 Novartis Ag Metodos para tratar cancer resistente a los farmacos.
KR101368519B1 (ko) 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
CA2627544C (en) 2005-11-29 2015-07-07 Novartis Ag Formulations of quinolinones for the treatment of cancer
US20080206194A1 (en) * 2007-02-16 2008-08-28 Glazer Robert I Method for the treatment of breast cancer
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion

Also Published As

Publication number Publication date
CN104093402A (zh) 2014-10-08
MX2014009303A (es) 2014-10-14
BR112014017985A2 (pt) 2017-06-20
IN2014DN05869A (pt) 2015-05-22
WO2013116293A1 (en) 2013-08-08
EP2809312A1 (en) 2014-12-10
JP2015505562A (ja) 2015-02-23
US20140378422A1 (en) 2014-12-25
RU2014135436A (ru) 2016-03-27
KR20140117457A (ko) 2014-10-07
AU2013215251A1 (en) 2014-08-14
CA2861377A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
AR122743A2 (es) Composición farmacéutica de antagonistas de unión al eje pd-1 e inhibidores de mek
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
UY36207A (es) Inhibidores de la syk
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112014016163A2 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
BRPI0906444A8 (pt) compostos de 4-piridinona e seu uso para câncer
BR112012031580A2 (pt) derivado de tetra-hidrocarbolina
BR112015029353A2 (pt) derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR112015019369A2 (pt) derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra)
BR112014029439A2 (pt) derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos
BR112013017362A2 (pt) composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BRPI1011851A2 (pt) Composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, epara tratar uma doença
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]